Abstract：
Major pathologic response (MPR) and pathologic complete response (pCR) are increasingly being used in non-small cell lung carcinoma neoadjuvant clinical trials as an early endpoint of survival. MPR for all histologic types of lung cancer is ≤ 10% of viable tumor, while pCR requires no viable tumor. The International Association for the Study of Lung Cancer multidisciplinary recommendation for the assessment of response in surgically resected lung carcinomas after neoadjuvant therapy was the first attempt to standardize grossing processing and microscopic evaluation.
摘要：
主要病理反应（MPR）和病理完全反应（pCR）越来越多地用于非小细胞肺癌新辅助临床试验，作为生存的早期终点。所有组织学类型肺癌的MPR≤10%的存活肿瘤，而pCR不需要存活的肿瘤。国际肺癌多学科研究协会对新辅助治疗后手术切除的肺癌反应评估的建议是首次尝试标准化加工和显微镜评估。
